Metabolic markers of diabetic conditions and methods of use thereof

A technology for metabolic markers, diabetes, applied in each individual publication, patent area, able to solve the problem that the combined form is not shown etc.

Inactive Publication Date: 2010-08-11
TETHYS BIOSCI
View PDF4 Cites 32 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, combinations of specific lipids that can be used to improve the prediction of insulin resistance or the diagnosis of diabetic conditions have not been shown

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Metabolic markers of diabetic conditions and methods of use thereof
  • Metabolic markers of diabetic conditions and methods of use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 3

[0131] Selected plasma metabolite concentrations that were reduced as a result of PPARs-gamma treatment included: molar composition of 20:4n6 in PC, CE, TG and / or total plasma lipids; molar composition of 18:1n9 in FA ; ● Molar composition of 22:6n3 in PC, CE, TG and / or total plasma lipids; ● Molar composition of 18:0 in PC and / or total plasma lipids; ● 18:2n6 in PC, molar composition of CE, FA, TG and / or total plasma lipids; molar composition of plasmalogen (dm) in PC, PE and / or total plasma lipids; and / or 20:3n6 in The molar percentage composition within PC, CE and / or total plasma lipids. Example 3 PPARs - alpha and -delta agonist therapeutic markers provide a diagnostic tool for therapeutic efficacy, safety and reversal of diabetic conditions Research Overview

[0132] A clinical study in 57 subjects compared the effects of 12 weeks of treatment with PPARs-delta modifier (5 mg / 10 mg) and PPARs-delta modifier (20 mg) compared to placebo. Plasma samples were obtained before...

Embodiment 4

[0142] Selected plasma metabolite concentrations that decrease as a result of PPARs-alpha or delta treatment include: molar percent composition of 18:1n9 in FA; molar 22:6n3 in PC, CE, TG and / or total plasma lipids Percent composition; • Molar percent composition of 18:2n6 within PC, CE, FA, TG and / or total plasma lipids. Example 4 Treatment Response Markers

[0143] Drugs targeting three PPARs (PPARs-α, PPARs-δ and PPARs-γ) are being used or have been used as potential antidiabetic agents. PPARs therapeutic combination markers are listed below to identify markers of therapeutic response. These markers are used to assess the effectiveness of using PPARs agents to treat diabetic conditions.

[0144] Metabolites elevated with improved treatment of oral glucose intolerance, insulin resistance and other diabetic conditions: 14:0 molar composition in TG and / or total plasma lipids; 16:0 in PC, TG and Molar percent composition of 16:1n7 in PC, CE, TG, FA and / or total plasma lipids...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Novel methods for assessing the state of a diabetic condition of a subject are described, comprising determining the amount of a metabolite in a sample from a body fluid or tissue of the subject. The methods may be used, for example, in diagnosing and monitoring insulin resistance, prediabetes, or the response to a drug which alters a diabetic condition.

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS [0002] This application claims US Provisional Application No. 60 / 902,976, filed February 22, 2007, US Provisional Application No. 60 / 931,766, filed May 24, 2007, and US Provisional Application No. 61 / 021,853, filed January 17, 2008 priority, said document is hereby incorporated by reference in its entirety. Background of the Invention [0003] 15 million people in the United States have type 2 diabetes. In human and economic terms, diabetes has become one of the most costly diseases in the country today. The cost of medical care and services to treat diabetes in 2002 was estimated at $91.8 billion. Other losses due to lost productivity, disability and premature death from diabetes amounted to $40.2 billion. With one million new cases diagnosed each year, many people don't realize they have the disease until they experience one of its life-threatening complications, including heart disease, stroke, and kidney disease. [0004...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/92
CPCG01N2800/042G01N33/6893G01N2500/00A61K38/00
Inventor S·M·沃特金斯M·M·维斯特
Owner TETHYS BIOSCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap